Clinical-stage biotech company Aeglea BioTherapeutics Inc. has named former AstraZeneca Plc lawyer Jim Kastenmayer as its new general counsel.
Kastenmayer joins Austin, Texas-based Aeglea after a year as general counsel of Viela Bio in Maryland, which was acquired in March by Horizon Therapeutics Plc. Before that, he was global legal director for Covid-19 vaccine maker AstraZeneca, where he worked for over seven years.
“Aeglea has the science, strategy and personnel in place to deliver on its mission of having an impact on the lives of patients with rare metabolic diseases,” Kastenmayer said in a Thursday statement. “I look forward to being part of the journey.”
Aeglea focuses on human enzyme therapeutics to treat rare metabolic diseases that affect chemical reactions in the body, according to the company’s website. It went public in 2016.
Kastenmayer began his career as a patent attorney with Finnegan, Henderson, Farabow, Garrett & Dunner and was later corporate counsel for MedImmune. He was also a fellow with the National Cancer Institute and the National Institutes of Health, according to his LinkedIn profile.
“With his broad experience at both big pharma and emerging biotech and a strong intellectual property background, Jim brings a depth of experience that will be valuable,” said Aeglea CEO Anthony Quinn in the statement.
Aeglea also named Evercore Inc. managing director Jonathan Alspaugh as its new chief financial officer earlier this month.